China Drug Delivery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

China Drug Delivery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The China drug delivery devices market is expected to register a CAGR of 9.3% over the forecast period, (2022-2027).

When the COVID-19 pandemic first appeared, the majority of pharmaceutical companies and governments worked to treat COVID-19 patients effectively and drug delivery devices were expected to play a vital role in that context. For instance, in September 2022, CanSinoBIO received approval for the recombinant COVID-19 vaccine (Convidecia Air) for Inhalation delivery in China. Convidecia Air provides a non-invasive option that uses a nebulizer to change liquid into an aerosol for inhalation through the mouth. Thus, the advancements in the delivery of vaccines for COVID-19, increase the demand for drug delivery devices which helps the market to grow in the forecast period.

The major factors attributing to the growth of the China drug delivery devices market are the growing burden of chronic diseases and increasing advancements in drug delivery technology. The increasing prevalence of chronic diseases has led to the increased use of drug delivery devices in common, particularly disposable syringes. For instance, according to the International Diabetes Federation, Diabetes Atlas 2021, the age adjusted comparative prevalence of the diabetes in china for 2021 is estimated as 10.6% and for 2030 as 11.8% and for 2045 as 12.5%. There is gradual raise in the prevalence of diabetes in China which is expected to have increase demand for prefilled syringes and autoinjectors in the forecast period.

Furthermore, as per the report titled "Cancer statistics in China and United States, 2022: profiles, trends, and determinants" published in March 2022, China is experiencing a greater incidence of cancers. In 2022 it is expected that there will be approximately 4,820,000 new cancer cases in China, in which the most common is of lung cancer. Thus the greater incidence of cancers has demand for drug delivery devices which are used in the treatment of cancers. The other factor helping the growth of the drug delivery devices market is the increasing technological advancement, which may be one of the key factors fueling the market growth during the forecast period.

However, the high cost of development for drug delivery devices may restrain market growth over the forecast period.

Key Market TrendsAuto-Injectors Segment is Expected to Dominate the Market During the Forecast Period

The auto-injectors segment is expected to witness significant growth owing to the factors such as collaborations and partnerships of companies for auto-injectors, convenient usage, and the increased burden of chronic diseases.

Moreover, in July 2021, ALK Abello and China Grand Pharma entered into an exclusive licensing agreement for adrenaline autoinjector ALK’s AAI Jext to launch the product in China. Also, a raise in the burden of chronic diseases increases the demand for self-injectable as it is convenient during treatment. For instance, according to the GLOBOCAN 2020 report, there are approximately 815,563 new cases of lung cancer, 555,477 cases of colorectal cancer, 478,508 cases of stomach cancer, 416,371 cases of breast cancer, and 410,038 cases of liver cancer. These chronic diseases increase the usage of self-injectable drug delivery devices like auto-injectors which are majorly used in the treatment. Also, according to the report published by the National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID) in October 2021, there are about 5 million rheumatoid arthritis patients in China in 2021, with an average onset age of 45 years. Hence, for treating the chronic diseases there is a need of self-injectable devices like auto-injectors which are convenient and easy to use. Thus the segment drives the growth of the market during study period.

Another growth driving factor is the new approvals and launches of drugs with auto-injector devices. For instance, in September 2020, China's National Medical Products Administration (NMPA) officially approved the Toujeo, Insulin Glargine (injector pen) for adults with type 2 diabetes who require insulin therapy. Thus the new approvals of the auto-injectors delivery drugs will drive the market growth through this segment.

Thus, due to the above-mentioned factors, the auto-injectors segment is expected to grow significantly during the forecast period.

Competitive Landscape

The China drug delivery devices market is highly competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market and some prominent players are vigorously making acquisitions and joint ventures with other companies to consolidate their market positions in the country. Some of the major players include Gerresheimer AG, Pfizer Inc., F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Novartis AG, Sanofi, GSK plc, and Baxter.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.